Cellectar Biosciences Inc.
CLRB | NASDAQ
$2.35
$0 (0.00%)
Sep 22, 2026, 11:26 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | -110.02K | -110.02K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 110.02K | 110.02K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -23.53M | -22.37M | -22.98M | -30.03M | -38.51M | -46.18M | -51.78M | -51.58M | -47.67M | -42.26M | -38.96M | -33.84M | -32.24M | -31.38M | -28.81M | -27.31M | -25.32M | -23.91M | -24.13M | -22.01M | -20.1M | -17.69M |
Interest Income | 406.47K | 361.13K | 435.1K | 581.74K | 787.08K | 1.03M | 1.21M | 1.11M | 839.09K | 582.96K | 387.15K | 395.37K | 348.42K | 276.12K | 152.52K | 5.08K | 1.5K | 1.68K | 3.61K | 3.61K | 3.4K | 13.05K |
Pretax Income | -22.32M | -20.84M | -21.79M | -18.79M | -29.01M | -24.48M | -44.52M | -50.17M | -53.02M | -62.28M | -42.83M | -47.36M | -37.65M | -34.9M | -33.85M | -27.3M | -25.31M | -23.9M | -24.12M | -21.82M | -19.91M | -17.49M |
Net Income | -22.32M | -20.84M | -21.79M | -18.85M | -29.07M | -24.54M | -44.58M | -50.11M | -52.96M | -62.22M | -42.77M | -47.3M | -37.59M | -34.84M | -33.79M | -27.3M | -25.31M | -23.9M | -24.12M | -21.82M | -19.91M | -17.49M |
Selling & General & Admin | 10.39M | 11.4M | 11.48M | 15.48M | 20.99M | 23.7M | 25.64M | 23.72M | 18.26M | 14.06M | 11.5M | 8.85M | 8.91M | 9.69M | 9.59M | 9.16M | 8.61M | 7.07M | 6.54M | 6.43M | 5.78M | 5.53M |
Research & Development | 13.25M | 11.08M | 11.5M | 14.55M | 17.52M | 22.48M | 26.14M | 27.86M | 29.4M | 28.19M | 27.47M | 24.98M | 23.33M | 21.69M | 19.22M | 18.15M | 16.71M | 16.84M | 17.59M | 15.57M | 14.32M | 12.16M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 23.64M | 22.48M | 22.98M | 30.03M | 38.51M | 46.18M | 51.78M | 51.58M | 47.67M | 42.26M | 38.96M | 33.84M | 32.24M | 31.38M | 28.81M | 27.31M | 25.32M | 23.91M | 24.13M | 22.01M | 20.1M | 17.69M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 833 | 833 | 833 |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 23.53M | 22.37M | 22.98M | 30.03M | 38.51M | 46.18M | 51.78M | 51.58M | 47.67M | 42.26M | 38.96M | 33.84M | 32.24M | 31.38M | 28.81M | 27.31M | 25.32M | 23.91M | 24.13M | 22.01M | 20.1M | 17.69M |
Income Tax Expense | n/a | n/a | n/a | 66K | 66K | 66K | 66K | -60K | -60K | -60K | -60K | -60K | -60K | -60K | -60K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 12.23M | 4.24M | 4.24M | 3.16M | 1.61M | 1.54M | 1.4M | 1.31M | 169K | 978.22K | 647.37K | 376.96K | 375.37K | 375.37K | 310.2K | 203.67K | 203.67K | 203.67K | 203.67K | 199.56K | 175.88K | 160.46K |
Shares Outstanding (Diluted) | 12.23M | 4.24M | 4.24M | 3.16M | 1.61M | 1.54M | 1.4M | 1.31M | 1.25M | 978.22K | 647.37K | 376.96K | 375.37K | 375.37K | 310.2K | 203.67K | 203.67K | 203.67K | 203.67K | 199.56K | 175.88K | 160.46K |
EPS (Basic) | -4.56 | -7.38 | -10.35 | -10.78 | -20.55 | -17.93 | -40.87 | -51.36 | -86.66 | -113 | -104.92 | -132.75 | -124.62 | -134.01 | -145 | -134.06 | -124.87 | -122.64 | -132.11 | -126.92 | -142.31 | -186.59 |
EPS (Diluted) | -4.56 | -7.38 | -10.35 | -10.78 | -20.55 | -22.59 | -45.53 | -56.02 | -91.32 | -113 | -104.92 | -132.75 | -124.62 | -134.01 | -145 | -134.06 | -124.87 | -122.64 | -132.11 | -126.92 | -142.31 | -186.59 |
EBITDA | -22.33M | -20.79M | -21.58M | -18.55M | -28.76M | -24.22M | -44.22M | -49.87M | -52.76M | -62.04M | -42.64M | -47.2M | -37.49M | -34.76M | -33.7M | -27.15M | -25.16M | -23.75M | -23.97M | -21.86M | -19.95M | -17.55M |
EBIT | -22.32M | -20.84M | -21.79M | -18.79M | -29.01M | -24.48M | -44.52M | -50.17M | -53.02M | -62.28M | -42.83M | -47.36M | -37.65M | -34.9M | -33.85M | -27.3M | -25.31M | -23.9M | -24.12M | -22.01M | -20.1M | -17.69M |
Depreciation & Amortization | -8.28K | 47.28K | 213.6K | 232.71K | 249K | 259.46K | 291.65K | 293.04K | 265.68K | 238.31K | 192.38K | 160.57K | 152.33K | 147.58K | 148.44K | 149.57K | 153.4K | 158.2K | 149.92K | 146.55K | 145.69K | 142.65K |
Add to Watchlist
Select watchlists to add or remove CLRB